Molecular Profiling Array for Cancer Specific Proteins

Information

  • Research Project
  • 6737925
  • ApplicationId
    6737925
  • Core Project Number
    R44CA096061
  • Full Project Number
    4R44CA096061-02
  • Serial Number
    96061
  • FOA Number
    PAR-01-107
  • Sub Project Id
  • Project Start Date
    6/20/2002 - 22 years ago
  • Project End Date
    6/30/2004 - 20 years ago
  • Program Officer Name
    HEATH, ANNE K
  • Budget Start Date
    7/1/2003 - 21 years ago
  • Budget End Date
    6/30/2004 - 20 years ago
  • Fiscal Year
    2003
  • Support Year
    2
  • Suffix
  • Award Notice Date
    7/22/2003 - 21 years ago
Organizations

Molecular Profiling Array for Cancer Specific Proteins

DESCRIPTION (provided by applicant): We will develop a protein detection chip that will allow parallel detection of proteins, including their modified forms. These chips, or molecular profiling arrays, will specifically focus on cancer related targets. This tool will allow researchers and clinicians to generate a molecular profile of cellular extracts. Our core technology, Riboreporters, are allosteric ribozymes whose activity is regulated by an effector molecule. By monitoring the activity of the Riboreporter, it is possible to infer the level of the effector (or target) molecule. Previously, it has been shown that Riboreporters can respond to a wide range of targets, including small molecules and proteins. During phase I, we will demonstrate a 2-element Riboreporter chip capable of specifically detecting ERK and phosphorylated-ERK in cellular extracts. This demonstration will allow us to critically evaluate important aspects of this technology, including: a) the ability to generate Riboreporters to cancer related targets; b) the ability to differentiate modified forms of the same protein; c) the ability to use Riboreporters in a high-throughput, chip-based format and d) the ability to use this chip in complex cellular extracts. During phase II, we will develop a larger scale chip for the analysis of cancer related targets. PROPOSED COMMERCIAL APPLICATION: This technology will be useful for cancer diagnostics, cancer research and the development of new therapeutic compounds.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R44
  • Administering IC
    CA
  • Application Type
    4
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    597770
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    396
  • Ed Inst. Type
  • Funding ICs
    NCI:597770\
  • Funding Mechanism
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ARCHEMIX CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    CAMBRIDGE
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02139
  • Organization District
    UNITED STATES